Cardiomyopathies Assessment and Management Quiz

Atrial cardiomyopathy is not classified as a type of cardiomyopathy.

Left ventricular hypertrophy is the hallmark feature of hypertrophic cardiomyopathy.

Echocardiography is commonly used for the diagnosis of cardiomyopathies.

Beta-blockers are typically used for symptomatic relief and management in dilated cardiomyopathy.

MYH7 is commonly associated with hypertrophic cardiomyopathy.

Amyloidosis is the primary cause of restrictive cardiomyopathy.

Normal coronary arteries on angiography are a characteristic feature of takotsubo cardiomyopathy.

Epinephrine has been implicated in the pathophysiology of stress-induced cardiomyopathy.

Beta-blockers are the primary treatment for stress-induced cardiomyopathy.

Replacement of myocardium with adipose and fibrous tissue is a feature of arrhythmogenic cardiomyopathy.

Myocarditis is the primary cause of dilated cardiomyopathy.

Peripartum cardiomyopathy occurs within 5 years postpartum.

Restrictive cardiomyopathy is characterized by impaired relaxation of the ventricles, leading to diastolic dysfunction.

Genetic mutations are the most common cause of hypertrophic obstructive cardiomyopathy (HOCM).

Cardiac MRI is particularly useful in diagnosing infiltrative diseases associated with restrictive cardiomyopathy.

Antiarrhythmic drugs are the primary treatment for arrhythmias associated with hypertrophic cardiomyopathy.

Fibrofatty replacement of myocardium is a characteristic feature of arrhythmogenic right ventricular cardiomyopathy (ARVC).

Septal myectomy is often considered in severe cases of hypertrophic obstructive cardiomyopathy (HOCM).

The main goal of pharmacological management in hypertrophic obstructive cardiomyopathy (HOCM) is to alleviate left ventricular hypertrophy.

Hypertrophic cardiomyopathy is often associated with a family history of sudden cardiac death.

Implantable cardioverter-defibrillator (ICD) is the mainstay of treatment for arrhythmogenic right ventricular cardiomyopathy (ARVC).

The initial management approach for cardiomyopathy patients presenting with acute heart failure is intravenous diuretics.

Digitalis glycosides are contraindicated in patients with hypertrophic obstructive cardiomyopathy (HOCM) due to their negative inotropic effects.

Implantable cardioverter-defibrillator (ICD) placement is the primary treatment strategy for arrhythmogenic cardiomyopathy.

Takotsubo cardiomyopathy is characterized by transient systolic dysfunction of the left ventricle typically triggered by emotional or physical stress.